Polar Asset Management Partners’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Polar Asset Management Partners’s Portfolio NKGNW Stock Details NKGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-60,000	Closed	-$6K	–	804
2024 Q4	$6K	Hold	60,000	–	–	﹤0.01%	642
2024 Q3	$4.24K	Hold	60,000	–	–	﹤0.01%	687
2024 Q2	$5.92K	Hold	60,000	–	–	﹤0.01%	665
2024 Q1	$8.4K	Hold	60,000	–	–	﹤0.01%	711
2023 Q4	$4.85K	Buy	+60,000	New	+$8.09K	﹤0.01%	738
2023 Q3	–	Sell	-60,000	Closed	-$12K	–	993
2023 Q2	$12K	Hold	60,000	–	–	﹤0.01%	851
2023 Q1	$8.41K	Hold	60,000	–	–	﹤0.01%	988
2022 Q4	$5.09K	Hold	60,000	–	–	﹤0.01%	1135
2022 Q3	$9K	Hold	60,000	–	–	﹤0.01%	1263
2022 Q2	$16K	Hold	60,000	–	–	﹤0.01%	1213
2022 Q1	$36K	Hold	60,000	–	–	﹤0.01%	1049
2021 Q4	$69K	Hold	60,000	–	–	﹤0.01%	1175
2021 Q3	$70K	Buy	+60,000	New	+$74.9K	﹤0.01%	1134

Other funds holding NKGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Polar Asset Management Partners's NKGNW Position: Q1 2025 in Review

Polar Asset Management Partners sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q1 2025, closing a stake of 60,000 shares — an estimated $6K sold.

Polar Asset Management Partners first reported a position in NKGNW in Q3 2021 and held it in 13 quarters. The position peaked at $70K in Q3 2021. 3 funds tracked by Wall St. Rank hold NKGNW as of Q1 2025.

Polar Asset Management Partners reported no remaining NKGen Biotech, Inc. Warrants position as of Q1 2025 after selling out during the quarter.
Polar Asset Management Partners sold 60,000 NKGen Biotech, Inc. Warrants shares in Q1 2025, an estimated $6K.
Polar Asset Management Partners first reported a position in NKGen Biotech, Inc. Warrants in Q3 2021 and held it in 13 quarters.
Polar Asset Management Partners's NKGen Biotech, Inc. Warrants position peaked at $70K in Q3 2021.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q1 2025.

Based on Polar Asset Management Partners's 13F filing for Q1 2025, filed 15 May 2025.